Replies to post #8152 on Synaptogenix Inc (SNPX)

[Cyosol]

I think something worth mentioning is that this stock is still very much under the radar, even after the recent volume boost.

For comparison, if we multiply closing prices with volume, we can see that about $3,295,618 worth of Neurotrope shares traded hands last week.

Meanwhile, a company like Biogen had about $2,213,555,948 worth of shares trade hands last week, which is almost 672 times more money.

[Wildginger]

This approach interested me. Gene therapy has along way to go in AZ but anything that can help without focusing on b amyloid seems like a step in the right direction
https://www.technologyreview.com/s/613001/doctors-plan-to-test-a-gene-therapy-that-could-prevent-alzheimers-disease/

[conix]

NTRP is also working on the only promising therapy for Alzheimer's. Not just delaying the progression of the disease, but possibly reversing it. The potential savings for our healthcare system is huge for the country and the world.

Should the trials validate its efficacy and safety, the FDA would be hard pressed not to give Bryostatin Fast Track status.